VEGFA and age-related macular degeneration: All the antiangiogenic agents currently used to treat age related macular degeneration will bind to VEGF-A, and therefore, regulate its binding to vascular endothelial growth factor receptor 2 (VEGFR2) and VEGFR1 [11,13].